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Tobacco smoking is t
of patients with lunghe most common cause of lung cancer, but approximately 10–25%
cancer are life-long never smokers. The cause of lung cancer innever smokers is unknown, although tobacco-smoke exposure may play a role in some
of these patients. Lung cancer that develops in the absence of significant tobacco-smoke
exposure appears to be a unique disease entity with novel genomic and epigenomic
alterations and activation of molecular pathways that are not generally seen in
tobacco-smoke-induced lung cancer. These molecular alterations are very likely respon-
sible for the unique clinico-pathological features of lung cancer in never smokers
(LCINS), and some of these molecular alterations – such as the activating EGFR TK muta-
tions and EML4–ALK fusion – significantly influence therapeutic choices and treatment
outcomes. In the last few years there has been a number of studies exploring the molec-
ular characteristics of LCINS, and some of them have reported new and significant find-
ings. Here we review the key findings from these studies and discuss their potential
therapeutic implications.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.1. Introduction
Globally, over a million patients are diagnosed with lung can-
cer each year, making it the most common type of cancer in
the world [1]. Even though tobacco smoking is considered to
be the most common cause of lung cancer, it is estimated that
10–25% of all patients diagnosed with lung cancer are never
smokers [2]. Never smokers with lung cancer are more likely
to be women, have adenocarcinoma histology and are of East
Asian ethnicity when compared to tobacco smokers with lung
cancer [3–5] Apart from these now well-established epidemi-
ological differences, recent research has uncovered several
key molecular alterations that are more frequently detected
in never smokers with lung cancer. Some of these molecular
alterations – such as activating mutations in the tyrosine ki-
nase (TK) domain of the epidermal growth factor receptor
(EGFR) gene and the EML4–ALK fusion – have therapeutic rel-
evance in the treatment of patients with advanced-stage lung
cancer [6–10]. Comprehensive genomic analysis by wholegenome sequencing has also identified significant differences
between the tumour genome of lung cancer in never smokers
(LCINS) and tobacco smokers with lung cancer [11] (Table 1).
In this review we will discuss the genomic and epigenomic
findings that characterise LCINS.
2. Inherited susceptibility to LCINS
Despite the fact that tobacco smoking is the primary cause of
lung cancer, identification of familial clustering of patients
with lung cancer is suggestive of an inherited risk factor. Sev-
eral studies have reported that patients with LCINS are more
likely to have a family member diagnosed with lung cancer
than a tobacco smoker with the same disease [12–15]. A sys-
tematic review of 11 studies identified that a positive family
history of lung cancer increases the risk of developing lung
cancer by 1.5-fold in never smokers [16]. A linkage study of
52 families with two or more members diagnosed with lung
cancer identified the 6q23–25 region to be a majorx 8056, St.
Table 1 – Characteristic molecular variations in lung cancer in never smokers (LCINS).
Markers Lung cancer in tobacco smokers LCINS
Genomic changes Point mutations in protein coding regions Primarily G ! T
transversions
Primarily G ! A
transitions
KRAS mutation Common, 30–43% Rare, 0–7%
EGFR mutation Rare, 0–7% Common, 45%
TP53 mutation; G ! T to G ! A ratio Ratio = 1.5 Ratio = 0.23
STK11 mutations 14% 3%
EML4-ALK fusion 2–3% 5–11%
ROS fusion <1% 1.5–6%
RET fusion <1% 2%
Epigenomic changes Methylation index (MI) High MI Low MI
p16 and APC methylation Common Rare
Loss of protein expression in hMSH2 Less common, 10% More common, 40%
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 4 8 –2 5 3 249susceptibility locus for lung cancer [17]. In addition, three
large genome-wide association studies (GWASs) identified
the 15q24–25.1 locus as the site harbouring genetic polymor-
phisms associated with lung cancer risk [18–20]. However, a
pooled analysis of data from all three studies did not find
the 15q24–25.1 locus to be associated with increased risk for
LCINS [21].
Studies have also examined whether polymorphisms of
genes involved in carcinogen metabolism, DNA repair and
inflammation are associated with increased risk for develop-
ing LCINS. Pooled analysis of studies evaluating CYP1A1 and
GSTM1 polymorphisms identified that CYP1A1-I462V poly-
morphism was associated with two- to three-fold increased
risk for developing LCINS. Interestingly, the CYP1A1-I462V
polymorphism was associated with increased risk for LCINS
only in Caucasians, not in Asians [22]. However, these find-
ings are limited by the small sample size of patients with
LCINS in each individual study, and they were focused on a
limited number of molecular alterations. Individual studies
have shown specific polymorphisms involving DNA repair
genes (XRCC1 and ERCC2) and genes involved in interleukin
production (IL1, IL6 and IL10) to be associated with increased
risk for LCINS [23–25]. These studies are limited by their rela-
tively small sample size and require independent validation
to ascertain that these polymorphisms are associated with in-
creased risk for LCINS.
3. Markers of tobacco exposure
Significant differences have been reported in the frequency
and patterns of gene mutations between LCINS and lung can-
cer in tobacco smokers (reviewed in [26]). Some of the earliest
studies identified that mutations in the tumour suppressor
gene TP53 were less frequent in LCINS (8–47%) when
compared with tobacco smokers with lung cancer (26–71%)
[27–29]. Also a significant dose–response relationship be-
tween tobacco smoke and TP53 mutations has been reported
in patients with non-small-cell lung cancer (NSCLC) [27]. In a
sample of 30 resected NSCLC tumor samples the odds of hav-
ing TP53 mutations in a patient smoking 20 cigarettes per day
for 30 years were 5.3 when compared with a patient with
LCINS. Tobacco-smoke exposure was also associated with a
distinct mutational spectrum in the TP53 gene, withincreased frequency of G ! T transversion mutations when
compared to LCINS [30,31].
Mutations involving the KRAS oncogene are rare in pa-
tients with LCINS and are more frequently reported in tobacco
smokers with lung cancer [32–36]. In a sample of 106 patients
with adenocarcinoma, the incidence of KRAS mutations was
significantly higher in the smokers cohort versus the never
smokers (43% versus 0%, P = 0.001) [35]. Similarly KRAS muta-
tions are more frequently identified in tobacco smokers and
are predominantly G ! T transversion mutations [31].
4. Fusions and mutations involving kinase
genes
Analyses of tumor samples from patients with excellent re-
sponse to treatment with EGFR TK inhibitors led to the dis-
covery of activating mutations involving the EGFR TK gene
[6,7]. At around the same time it was also discovered that pa-
tients with LCINS had a better response to EGFR TK inhibitors
such as gefitinib [37]. Several retrospective studies subse-
quently established that patients with LCINS were more likely
to harbour the EGFR TK mutation than tobacco smokers with
lung cancer [8,38,39]. One of the largest studies (n = 1082) con-
firmed that activating EGFR TK mutations were more frequent
in patients with LCINS than in tobacco smokers with lung
cancer: 54% versus 16% [40]. The higher incidence of EGFR
TK mutations in LCINS has been a consistent finding across
different ethnic and geographical divisions. In addition, the
frequency of EGFR TK mutations is inversely related to tobac-
co-smoke exposure. The proportion of EGFR TK mutations in
patients with less than 20 pack year exposure was 55% versus
27% for 20–50 pack years and 22% for >50 pack years
(P < 0.001) [38]. Pham and colleagues reported similar findings:
decreasing incidence of EGFR TK mutations with increasing
pack years [39]. The difference was significant when exposure
was >15 pack years (9%) versus never smokers (51%); P < 0.005.
In addition, EGFR TK mutations were not detected in tobacco
smokers with more than 75 pack year exposure.
The EGFR TK inhibitor erlotinib was initially approved for
the treatment of all patients with advanced NSCLC in the
second- and third-line settings. The discovery of activating
EGFR TK mutations led to several randomised trials compar-
ing EGFR TK inhibitors with chemotherapy in the front-line
250 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 4 8 –2 5 3setting in patients with EGFR TK mutations [41–43]. Results
from these trials have now established EGFR TK inhibitors
as the standard front-line treatment for patients with ad-
vanced-stage NSCLC that is positive for EGFR TK mutation.
Mutations involving the HER2 gene have been shown to be
more frequent in never smokers with adenocarcinoma [9]. In
a sample of 671 NSCLC tumours, the overall frequency of
HER2 mutations was low at 1.6% (11/671), but they were more
frequently identified in never or light smokers (8 of 248, 3.2%;
P = 0.02). The HER2 mutations were not detected in tumours
harbouring either the activating EGFR-TK or KRAS mutations.
The STK11 gene encodes a serine–threonine kinase and
plays an important role in cell proliferation and survival.
Mutations involving the STK11 gene have been reported in
8% of all patients with lung cancer. In addition, they are more
frequently present in tobacco smokers with lung cancer than
in patients with LCINS (14% versus 3%; P = 0.007) [44].
EML4–ALK is a novel fusion gene present in approximately
5% of patients with NSCLC and is associated with an excellent
therapeutic response to treatment with an Alk kinase inhibi-
tor [10,45,46]. The fusion gene was more frequently identified
in never smokers and younger patients with lung cancer. In
addition, it appears to be mutually exclusive to EGFR TK and
KRAS mutations.
Two new transforming fusions involving the RET and ROS1
kinase genes at the 3 0 end have been identified in patients
with lung cancer [47]. In one study, tumour samples from
936 patients with surgically resected NSCLC were tested for
RET fusion genes by the reverse transcriptase polymerase
chain reaction (PCR). The RET fusion was detected in 13 pa-
tients (1.4%), and these patients predominantly had adeno-
carcinoma histology (84.6%), were never smokers (82%) and
many of them were younger: age 6 60 years at the time of
diagnosis (73%) [48]. RET fusions have been shown to promote
cell proliferation, and treatment with vandetanib, a multi ki-
nase inhibitor with activity against RET kinase, was able to in-
hibit RET-induced cell proliferation [47]. Fusions involving the
ROS1 gene in lung cancer were first reported in 2007 [49] and
in a subsequent study, a fluorescent in situ hybridisation
(FISH) based assay of 1000 NSCLC tumour samples identified
ROS1 fusions in 18 (1.7%) samples [50]. Similar to patients
with ALK or RET fusions, ROS fusions were found primarily
in younger patients who were never smokers and had adeno-
carcinoma histology. Cell lines expressing ROS fusion were
sensitive to treatment with the ALK inhibitor crizotinib. Over-
all, fusion genes involving the ALK, RET and ROS kinases are
relatively rare molecular events in patients with NSCLC.
These patients have similar clinico-pathological features,
including that of being a never smoker. In addition, these fu-
sions appear to be mutually exclusive to each other and to
other known driver mutations in lung cancer, such as EGFR
TK and KRAS mutations.
5. Epigenetic alterations
Methylation of tumour suppressor genes – including p16INK4a,
DAPK, RASSF1A, RARb, APC, CDH13, MGMT, hMLH1, hMSH2 and
GSTP1 – leading to epigenetic silencing has been reported in
lung cancer (reviewed in [51,52]). Studies have reported thatmethylation of the tumour suppressor gene p16 is less fre-
quent in LCINS in comparison to lung cancer in tobacco
smokers [53–57]. In a sample of 514 NSCLC tumours, which
included 112 never smokers with adenocarcinoma, p16
(P = 0.007) and APC (P = 0.0007) methylation rates were signif-
icantly lower in never smokers than tobacco smokers with
adenocarcinoma [54]. There was no significant difference in
the methylation rate of the other tumour suppressor genes
RASSF1A, RARb, CDH13, MGMT and GSTP1 between the two
groups. The methylation index (total number of genes meth-
ylated/total number of genes examined) was significantly
higher in tobacco smokers with lung cancer when compared
to LCINS. In a follow-up study of 383 NSCLC tumours, the
authors confirmed that the p16 methylation rate and the
methylation index were significantly lower in LCINS
(P < 0.0001) [55]. The methylation rate for APC was signifi-
cantly lower (P < 0.0001) in never smokers when the analysis
was restricted to adenocarcinoma. Subsequent studies have
also reported a low p16 methylation rate in never smokers
with adenocarcinoma [56,58]. There was no significant differ-
ence in the methylation rates of RASSF1A and DAPK between
tobacco smokers with lung cancer and LCINS [56].
The loss of protein expression in protein mismatch repair
genes hMLH1 and hMSH2 was reported to be more frequent in
LCINS than in lung cancer in tobacco smokers [59]. In a sam-
ple of 77 resected NSCLC tumours, the loss of protein expres-
sion for hMLH1 (70% versus 46%) and hMSH2 (40% versus 10%)
was more frequent in LCINS. The authors also reported that
promoter methylation was the predominant mechanism for
the loss of protein expression in both genes.6. Next-generation sequencing in LCINS
The advent of next-generation sequencing technologies now
allows us unprecedented access to the tumour genome. Re-
cently, next-generation sequencing of several tumour–normal
pairs from patients with NSCLC was reported, and some of
these patients were never smokers. Whole genome and tran-
scriptome sequencing was performed in 17 patients with
NSCLC, including five never smokers and 12 tobacco smokers
[11]. The total number of mutations involving genes in protein
coding regions was significantly higher in smokers than in
never smokers; median 209 versus 18. In addition, the muta-
tions in tobacco smokers were primarily G ! T transversions,
whereas in LCINS they were G ! A transitions. For the first
time this study identified that the G ! A transition point
mutations in never smokers is a genome-wide phenomenon
and is not restricted to KRAS and TP53 genes.
Genomic and epigenomic profiling of tumour–normal
pairs from six Korean patients with LCINS with exome seq,
RNA seq, micro RNA seq and methylated DNA immunopre-
cipitation-sequencing (MeDIP-seq) confirmed the low muta-
tion rate in LCINS [60]. They reported a total of 47 somatic
mutations from the six LCINS tumour samples. In addition,
they identified several novel fusion genes, including CCDC6–
RET fusion which has been previously reported and could be
a potential therapeutic target. Pathway analysis identified
that genes involved in cell cycle regulation – particularly in
Fig. 1 – Circos plots of tumour genome from a never smoker with lung cancer and a tobacco smoker with lung cancer. Adapted
from Govindan et al [11].
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 4 8 –2 5 3 251G2/M transition – are very likely to have played a significant
role in the development of these tumours.7. Conclusion
Cancer is a disease that is characterised by genomic and epi-
genomic alterations that result in malignant transformation
of normal tissue. Such transforming genomic and epigenomic
alterations are considered the drivers of the malignant dis-
ease and determine the clinical behaviour of the disease. In
the case of lung cancer, tobacco-smoke exposure appears to
be an important factor in determining the type of oncogenic
drivers associated with the disease. This is well exemplified
by findings from several studies showing that mutations
involving TP53 and KRAS genes are more frequent in tobacco
smokers with lung cancer, whereas LCINS is characterised by
EGFR TK mutations, ALK, RETand ROS fusions. The differences
between LCINS and lung cancer in tobacco smokers are not
restricted to a few genes. Recent next-generation sequencing
studies have found that the genome of LCINS is significantly
different from the tumour genome of a tobacco smoker with
lung cancer (Fig. 1). Overall, the number of mutations is sig-
nificantly lower in LCINS, and the point mutations are primar-
ily G ! A transitions.
The higher number of genomic alterations seen in smok-
ers with lung cancer is very likely due to the mutagenic field
effect of tobacco-smoke exposure. The vast majority of these
genomic alterations in tobacco smokers with lung cancer are
believed to be passengers that do not have any role in the
malignant transformation or progression. In contrast, in
LCINS the absence of tobacco-smoke exposure and the
relatively smaller number of identified genomic alterations
suggest that most if not all of them play a role in its malignant
transformation. Hence the LCINS genome may provide us
with a relatively enriched and easily identifiable set of
oncogenic drivers for lung cancer. In addition, the relatively
small number of genomic alterations in LCINS also presents
better opportunities for the development of targeted thera-pies against LCINS. With the advances in sequencing technol-
ogy and decreasing costs it is possible that, in the near future,
advanced-stage LCINS may be primarily treated with molecu-
larly targeted therapy, and it would be possible to achieve pro-
longed periods of disease control similar to the treatment of
chronic myeloid leukaemia (CML) and gastrointestinal stro-
mal tumour (GIST).
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